Background {#Sec1}
==========

Colorectal cancer (CRC) is one of the major causes of cancer-related mortality with over 1 million new cases diagnosed worldwide each year \[[@CR1], [@CR2]\]. It is viewed as a heterogeneous disorder due to its molecular features and relevant subtypes, and can be divided into five molecular subtypes correlated to tumor morphological features with different DNA microsatellite instability status and CpG island methylator phenotype \[[@CR1]\]. Notably, KRAS mutation is closely linked to villous change and dysplasia \[[@CR2]\]. Adenocarcinoma with KRAS mutation that is considered a subgroup of CRC show a negative treatment response to epidermal growth factor receptor (EGFR)-targeted antibodies \[[@CR3]\]. Furthermore, KRAS mutation is an established biomarker in clinical practice for CRC and is associated with distant metastasis \[[@CR4]\], and poorer survival in CRC \[[@CR5]--[@CR7]\]. Approximately 30--40% CRCs have KRAS mutation, while rectal cancer accounts for 30--35% among CRC \[[@CR8], [@CR9]\]. The pre-operative neoadjuvant therapy including anti-EGFR chemotherapy has shown robust value in the management of rectal cancer \[[@CR3]\]. Therefore, it is important to select suitable patients who could benefit from aggressive multimodality approaches and to tailor individual treatments against the disease.

Currently, information pertaining to the KRAS status can only be gathered from the biopsy samples or postoperative specimens. Furthermore, the limitations of histological evaluation of KRAS status, such as the variability in the tissue sample and the poor DNA quality in sample results, can lead to discordance between biopsy material and final operative results \[[@CR10]\]. Thus, efficient identification of KRAS status in patients with rectal cancer using non-invasively method would be of great clinical interest.

On the other hand, different molecular subtypes correlate with various discriminating morphological features \[[@CR1]\]. Various MR imaging modules \[[@CR11]--[@CR16]\] (i.e. diffusion-weighted MR imaging \[DWI\], magnetic resonance spectroscopy \[MRS\], arterial spin labelling \[ASL\]) and advanced analysis for routine MR imaging \[[@CR17]--[@CR21]\] have been introduced in the oncologic field to evaluate tumoral biological characteristics and predict KRAS status. Nevertheless, the radiologic features of rectal cancer with KRAS mutation have not yet been fully described. Texture analysis is a noninvasive method used for assessment of the intra-tumoral heterogeneity not perceptible by human eye, which has a promising value in predicting therapy response, survival and discriminating different stages in rectal cancer \[[@CR22]--[@CR24]\]. However, to date, there have been no studies to assess whether texture analysis of MRI can be used as an imaging biomarker for KRAS status in rectal cancer.

Hence, the main objects of the present study were to 1) retrospectively analyze the differences of radiologic features in rectal cancer with different KRAS status; 2) investigate whether texture features extracted from T2 weighted image scan differentiate KRAS mutation status in rectal cancers.

Methods {#Sec2}
=======

Patients and tissue samples {#Sec3}
---------------------------

This retrospective study was approved by the institutional review board of Institute of Clinical Medicine, China-Japan Friendship Hospital (No. 2015--012), and written informed consent was waived. A total of 220 patients underwent rectal resection for adenocarcinoma with complete clinical data and preoperative pelvic MR examination (including T2WI-high resolution sequence) between June 2013 and September 2015. Exclusion criteria included: i) pre-examination neoadjuvant chemoradiotherapy (*n* = 45) or unidentified herbal medicine therapy (*n* = 5); ii) poor image quality \[heavy intestinal peristalsis artifacts (*n* = 10), too small lesions (diameter \< 5 mm) or lesions difficult to identify on DWI images (*n* = 2)\]. Finally, the group included in the study comprised 158 patients (106 men, 52 women) with a mean age of (60.66 ± 13.38) years (range 26--87 years). Among the 158 subjects, the data of 45 subjects were previously analyzed with a different objective for other research \[[@CR18]\].

Surgical pathology results from all patients were analyzed by a pathologist with 6 years' experience in gastrointestinal pathological diagnosis. Genomic DNA was extracted from formalin fixed paraffin-embedded (FFPE) tissue using QLAamp DNA FFPE Tissue kit (Qiagen, Germany), and KRAS mutations were examined by amplification refractory mutation system (ARMS) method.

Patient preparation and imaging protocol {#Sec4}
----------------------------------------

Patients were on a low-residue diet before the exam and fasted on the day of the exam. Intramuscular injection of 10 mg anisodamine hydrochloride was given to each patient to inhibit the intestine peristalsis some 10 min before MRI examination. Pelvis MR scanning was implemented on a 3 T whole-body scanner (Ingenia, Philips Medical Systems, Best, the Netherlands) with gradient strength 45mT/m and gradient slew rate 200mT/m/ms, using a 16-channel anterior torso dS coil and a 16-channel posterior table dS coil. 2D sagittal and coronal T2W TSE sequences were performed with following parameters: TR 3761 ms, TE 110 ms, FOV 24 × 24 cm, slice thickness 3 mm with 0.3 mm gap, acquisition matrix 336 × 252, NSA 3. Oblique axial T2W-high resolution sequence was planned perpendicularly to the bowel with tumor: TR 3865 ms, TE 100 ms, FOV 14 × 14 cm, slice thickness 3 mm with 0.3 mm gap, acquisition matrix 232 × 228. Oblique axial diffusion weighted imaging (DWI) scan perpendicularly to the tumor was implemented using a single-shot echo planar imaging with following parameters: TE/TR 76/6000 ms, FOV 20 × 30 cm, slice thickness 5 mm with 0.2 mm gap, acquisition matrix 292 × 304, NSA 6, 2 b values (0,1000s/mm^2^).

Image analysis {#Sec5}
--------------

All the data was transmitted to picture archiving and communication system (PACS) and Philips post-processing workstation. Two radiologists (with 11 and 7 years in gastrointestinal imaging), who were blinded to all clinical information, independently measured and recorded the following tumor features: tumor type, location, length, morphologic features, circumferential extent, T staging and the maximal extramural depth (MEMD) of tumor, N staging, circumferential resection margin (CRM), extramural vascular invasion (EMVI), ADC values, textural features. However, they were aware that the study subjects were patients with rectal cancers. For continuous variables, an average value of two observers' measurement was selected. For categorical variables, the diagnosis was determined after renegotiation by two observers if any interobserver discrepancies occurred.

### Tumor type {#Sec6}

According to the signal intensity of rectal cancers on T2WI \[[@CR25]\], the hyperintensity was defined as a signal intensity that was similar to or brighter than the perirectal fat. Each observer quantitatively evaluated hyperintense volume in the tumor and determined the type of tumor as "mucinous" or "non-mucinous" according to the same criteria used for pathologic diagnosis (at least≥50% of the mucin pool occupying the tumor mass \[[@CR26]\].

### Tumor location and length {#Sec7}

Tumor location, as well as tumor length were primarily evaluated on sagittal T2-weighted images. Axial and coronal T2-weighted images were used secondarily when required. The rectum was generally divided into three parts according to the anatomic distance from the anal verge: the upper third (\> 10 cm), middle third (5-10 cm), lower third(\< 5 cm). The anal verge was defined as the end of the anal canal \[[@CR27]\]. The distance between the lower margin of rectal lesion and anal verge were measured by drawing along the midline of rectal lumen in a zigzag pattern \[[@CR28]\]. Tumor length was also measured along the intestinal lumen in a zigzag pattern.

### Morphologic criteria/tumor shape {#Sec8}

Tumor shapes were classified \[[@CR27]\] as (a) intraluminal polypoid lesion (without abutting pericolorectal tissues) (Fig. [1](#Fig1){ref-type="fig"}); (b) ulcerofungating/ulceroinfiltrative mass (Fig. [2](#Fig2){ref-type="fig"}); (c) bulky (Fig. [3](#Fig3){ref-type="fig"}). If the tumor showed growth tendency of protruding mass into colorectal lumen or limited thickening-wall with a sharp margin from the adjacent normal intestinal wall, without breaching the outer margin, it was considered as the intraluminal polypoid lesion. If the tumor demonstrated wall-thickening grow tendency with abutting pericolorectal tissue, and MEMD \< 10 mm, it was considered as the ulcerofungating/ulceroinfiltrative mass. If the tumor showed exophytic growth tendency with disproportionately expanding component outside the imaginary line of the main tumor (MEMD≥10 mm), and the outer diameter of the tumor-bearing segment was larger than that of the adjacent normal colorectal segment, then it was considered a bulky mass. Fig. 1Sagittal T2-weighted imaging of a rectal cancer (intermediate signal intensity) presenting as polypoid mass (arrows) protruded into lumen with distinct intestinal wall (arrow head). Result of the postoperative pathology confirmed that the tumor invaded the submucosa without extending into muscularis propria Fig. 2T2-weighted imaging of a rectal cancer (low to intermediate signal intensity) presenting as ulceroinfiltrative mass (**a**, oblique axial, outline indicates tumor region) mainly extended along the intestinal wall with ambiguous muscularis propria (**b**, coronal, arrow head). Final pathologic results demonstrated that tumor invaded through muscularis propria to perirectal tissues Fig. 3Oblique axial T2-weighted imaging of a rectal mucinous adenocarcinoma (intermediate to high signal intensity) presenting as bulky mass showed significant tumor infiltration beyond the muscularis propria; the maximal extramural depth (MEMD, double-headed arrow) was over 10 mm. Meanwhile, the invasive border of rectal mass bordering the mesorectal fascia (white arrow) which leaded to a CRM of 0 mm. White line = muscularis propria border. Black dashed line = the mesorectal fascia

### Circumferential extent {#Sec9}

Axis bowel (clock face) was divided into quarters, C1: tumor extent≤1/4 bowel circumference; C2: tumor extent\> 1/4 bowel circumference and ≤ 1/2 bowel circumference; C3: tumor extent \> 1/2 bowel circumference and ≤ 3/4 bowel circumference; C4: tumor extent \> 3/4 bowel circumference.

### Tumor and node staging {#Sec10}

Primary tumor and lymph node stage were observed on MRI \[[@CR29]\] by using the Tumor-Node-Metastasis (TNM) staging system. Meanwhile, the MEMD of tumor was recorded, and T3 sub-stages were then classified \[[@CR30]\] according to different MEMD. T3 sub-stage: T3a: MEMD \< 1 mm beyond muscularis propria; T3b: MEMD ≥1-5 mm beyond muscularis propria; T3c: MEMD \> 5-15 mm beyond muscularis propria; T3d: MEMD \> 15 mm beyond muscularis propria. Nodes with irregular borders, mixed signal intensity, or both were suspected for metastasis, and presence of one to three suspicious nodes was defined as stage N1 and presence of four or more as stage N2.

### CRM {#Sec11}

The potential positive margin was defined as rectal tumor spread within 1 mm of the mesorectal fascia (Fig. [3](#Fig3){ref-type="fig"}), that occurred due to tumor deposits, tumor extramural extent, EMVI, or suspicious lymph nodes \[[@CR30]\].

### EMVI {#Sec12}

EMVI was defined as the presence of rectal tumor cells within blood vessels located beyond the muscularis propria in the mesorectal fat \[[@CR30]\]. The following clues for EMVI (Fig. [4](#Fig4){ref-type="fig"}) were (a) vessel expanded by tumor, having irregular contour; (b) presence of tumor signal intensity within vascular structure. Fig. 4Extramural vascular invasion (EMVI) involvement. Coronal T2-weighted imaging showing focal expansion of the small perirectal vessel with intermediate signal intensity (black arrow head)

### ADC evaluation {#Sec13}

Images of diffusion-weighted (DW) sequence were transferred to the Extended Workspace 4.1 (Philips Medical Systems, Best, Netherlands). Regions of interest (ROIs) were manually drawn to cover the entire tumor area on the axial slices containing all available tumor areas, which appeared as high signal on the DW images, avoiding the gas in the bowel and other anatomy structures.

### Textural features {#Sec14}

For each tumor, consecutive three axial T2W images (encompassing the tumor maximum cross-section as the middle slice) were conducted for textural analysis by using MaZda, version 4.6 (P.M. Szczypiński, Institute of Electronics, Technical University of Lodz, Poland). Freehand ROIs were delineated with the tumor contour on axial images avoiding the inclusion of intestinal gas, liquid and anatomical structures. Although contouring was performed using T2WI images, the observers looked at DW images, when available, to most accurately place the ROI.

Prior to analysis, MR image intensities were normalized between the range \[μ-3σ, μ + 3σ\], where μ was the mean value of gray levels inside the region of interest and σ denoted the standard deviation. Gray levels between \[μ-3σ\] and \[μ + 3σ\] were then decimated to 64 Gy levels. This normalization procedure has been shown to minimize inter-scanner effects in MRI feature analysis \[[@CR31]\]. Given that this analysis produced much more features than positive cases in the study, only first-and second-order texture features (three features) were selected for further analysis to avoid overfitting \[[@CR32], [@CR33]\]. Totally, 25 parameters, which are listed in Table [1](#Tab1){ref-type="table"}, were extracted for each ROI on each slice. Run-length matrix (RLM) parameters were calculated four times for each ROI (vertical, horizontal, 45°, 135°) and grey-level co-occurrence matrix (GLCM) parameters were calculated 20 times for each ROI at a variety of pixel offsets. For the comparison of textural features between tumors with different KRAS status, the mean value of gray-level histogram, RLM and GLCM parameters were used for each ROI, providing in total 25 parameters for analysis. Then, three parameters derived from gray-level histogram (*Mean*, *Variance*, *Skewness*), one parameter from gray-level co-occurrence matrix (GLCM) (*Entropy*) and two parameters from RLM (*gray-level nonuniformity* \[GLNU\],*run-length nonuniformity* \[RLNU\]) were extracted for each of the three slices based on the probability of classification error and the average correlation coefficients (POE + ACC) \[[@CR34]\]. The detailed description of the calculated texture parameters was provided by Haralick et al. \[[@CR35]\]. Table 1Summary of parameters belonging to first- and second-order texture features^33-35^Texture featureHistogram (*n*=9)Run-length matrix (*n*=5)Grey-level co-occurrence matrix (*n*=11)Level/OrderFirst orderSecond orderSecond orderDescriptionHistogram where x-axis represents pixel/voxel gray level and y-axis represents frequency of occurrenceAdjacent or consecutive pixels/voxels of a single gray level in a given directionHow often pairs of pixels with specific values in a specified spatial range occur in an imageParametersMeanShort run-length emphasisAngular second momentstandard deviationLong run-length emphasisContrastskewnessRun-length non-uniformityCorrelationKurtosisGrey-level non-uniformitySum of squaresPerc.1%Fraction of image in runsInverse difference momentPerc.10%Sum averagePerc.50%Sum variancePerc.90%Sum entropyPerc.99%EntropyDifference varianceDifference entropy

The selected feature sets were evaluated using the computer program B11, which is part of the MaZda software package. Artificial neural network (ANN) classifier \[[@CR34]\] was employed for investigating the ability of texture feature sets to distinguish between rectal cancers with different KRAS status. The classification results were arbitrarily divided into several levels according to the misclassification rates: excellent (misclassification rates≤10%), good (10% \< misclassification rates≤20%), moderate (20% \< misclassification rates≤30%), fair (30% \< misclassification rates≤40%), and poor (misclassification rates≥40%) \[[@CR36]\].

Statistical analysis {#Sec15}
--------------------

The statistical analysis was performed by SPSS (SPSS 17.0 for Windows, SPSS, Chicago, IL). The Kolmogorov-Smirnov test for normality was performed on continuous variables and the graphical spread of the data was visually inspected. Descriptive statistics were shown as mean ± standard deviation (SD) or median ± interquartile range (IQR) for continuous variables, and as frequency and percentage for categorical variables. Interobserver agreement for continuous variables (ADC values, tumor length, MEMD, textural parameters) was evaluated using the intra-class correlation coefficient (ICC), and for categorical variables using Kappa of agreement. The Kappa value was interpreted as follows: \< 0, poor agreement; 0 to 0.20, slight agreement; 0.21 to 0.40, fair agreement; 0.41 to 0.60, moderate agreement; 0.61 to 0.80, substantial agreement; and \> 0.80, almost perfect agreement.

Patients were stratified into two groups: KRAS wild-type group (KRAS^wt^ group) and KRAS mutation group (KRAS^mt^ group) according to genomic DNA extraction and analysis. Mann-Whitney U test was used to compare variables (MEMD, texture features) with abnormal distribution for differentiation of rectal cancers with different KRAS status. The independent samples *t* test was used to compare other continuous variables (including ADC values, length and patients' age) between KRAS^wt^ and KRAS^mt^ group. Then, the differences among the other categorical variables were analyzed using the chi-square test or Fisher exact test. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the discriminatory power of MRI features including ADC values, tumor shape, T stage and textural features in differentiating tumor KRAS mutation. The area under the curve (AUC) and optimal cutoff values were calculated, as well as the corresponding sensitivity and specificity. *P*\<0.05 indicated a statistically significant difference.

Results {#Sec16}
=======

Patient characteristics {#Sec17}
-----------------------

Of 158 patients (mean age, 60.66 ± 13.38), 143 (90.51%) had cancers detected according to symptoms such as abdominal pain, hematochezia, changes in bowel habits and diarrhea, 10 (6.33%) had screen-detected cancers, and the cancers in the remaining 5 patients (3.16%) were discovered during the examination for other diseases. According to final pathological results, 98 (62.03%) had KRAS^wt^ and 60 (37.97%) had KRAS^mt^ type cancer. MRI features and patients' clinical characteristics in KRAS^wt^ group and KRAS^mt^ group are shown in Table [2](#Tab2){ref-type="table"}. Table 2MRI features and clinical characteristics of patients with rectal cancer(n=158)FactorsTotal (No./values)KRAS Status*P*-valueWild-type\
(*n*=98)Mutant\
(*n*=60)Age60.66±13.3860.42±12.8961.07±14.260.388Gender0.769 Male10666(67.35%)40(66.67%) Female5232(32.65%)20(33.33%)ADC (×10^-3^mm^2^/ms )1.22±0.391.37±0.371.15±0.380.008^\*^Texture features Mean66.47±14.5562.66±10.5373.34±18.38\<0.0001 Variance289.19±118.96267.65±122.51334.39±94.27\<0.0001 Skewness0.54±0.670.43±0.530.73±0.42\<0.0001 Entropy1.89±0.231.80±0.191.97±0.14\<0.0001 RLUN178.38±65.19159.87±53.38208.12±69.14\<0.0001 GLUN7.53±3.446.55±2.839.26±3.33\<0.0001Tumor location Upper Rectum4833(33.67%)15(25.00%)0.095 Middle Rectum7247(47.96%)25(41.67%) Lower Rectum3818(18.37%)20(33.33%)Tumor shape0.022 Intraluminal polypoid mass4031(31.63%)9(15.00%) Ulcerofungating/Ulceroinfiltrative mass9557(58.16%)38(63.33%) Bulky2310(10.20%)13(21.67%) Tumor length(cm)4.12±1.684.04±1.624.25±1.780.446^\*^Tumor type0.556 Mucinous adenocarcinoma2313(13.27%)10(16.67%) Non-mucinous adenocarcinoma13585(86.73%)50(83.33%)Cirumferential extent0.872^\*\*^ C164(4.08%)2(3.33%) C25636(36.73%)20(33.33%) C35634(34.69%)22(36.67%) C44024(24.49%)16(26.67%)Radiologic T stage0.029 T1-24935(35.71%)14(23.33%) T39458(59.18%)36(60.00%) T4155(5.10%)10(16.67%)T3 substage0.041 T3a2319(32.76%)4(11.11%) T3b3623(39.66%)13(36.11%) T3c2311(18.97%)12(33.33%) T3d125(8.62%)7(19.44%)MEMD(cm)0.30±0.600.30±0.600.50±0.600.028^\*^N stage0.754 N07448(48.98%)26(43.33%) N15131(31.63%)20(33.33%) N22319(19.39%)14(23.33%)EMVI0.664 Positive3420(20.41%)14(23.33%) Negative12478(79.59%)46(76.67%)CRM0.337 Positive3828(28.57%)13(21.67%) Negative12070(71.43%)47(78.33%)*Abbreviations*: *ADC* apparent diffusion coefficient, *MEMD* the maximal extramural depth of tumour; *EMVI* extramural vascular invasion, *CRM* circumferential resection margin, *RLNU* run-length nonuniformity, *GLNU* grey-level nonuniformity\*independent samples t test, data is mean ± standard deviation;Δ Mann-Whitney U test, data is data is median ± interquartile range. \*\*Considering limited patients' numbers in subgroups of circumferential extent, reclassification was adopted as follows: C1-2, C3, and C4, and *P* value was the result of new categorization

Quantitative textural analysis and ADC {#Sec18}
--------------------------------------

Mean values of six texture features were significantly different in rectal cancers with different KRAS status (*p* \< 0.0001). In addition, good classification results (error of 12.7%) were obtained with ANN classifier. Lower ADC values were observed in the KRAS^mt^ group compared to the KRAS^wt^ group (*t* = − 2.708, *p* = 0.008). The observed results are listed in Table [2](#Tab2){ref-type="table"}.

Conventional imaging analysis {#Sec19}
-----------------------------

With regard to tumor shape, the shape distribution between the two groups was quite different (*x*^2^=7.591, *p* = 0.022), with higher incidences of bulky (21.67%) and less intraluminal polypoid mass (15.00%) in the KRAS^mt^ group compared to (10.20 and 31.63%, respectively) KRAS^wt^ group, respectively. In addition, higher T stage was observed more frequently in the KRAS^mt^ group compared to the KRAS^wt^ group (*x*^2^=7.086, *p* = 0.029). Moreover, the mean MEMD in the KRAS^mt^ group was significantly larger than in the KRAS^wt^ group (Z = -2.202, *p* = 0.028), and relevant T3 sub-stage distribution in two groups showed a similar trend (*x*^2^=8.240, *p* = 0.041).

Although rectal cancers with KRAS mutation were mainly located in the middle-low part of rectum and had an extent of over 3/4 bowel circumference, there was no statistical difference between the KRAS^mt^ group and the KRAS^wt^ group (*p* = 0.095 and 0.872, respectively). Other imaging features including length, N staging, EMVI, CRM also demonstrated no significant difference between the two groups. Moreover, the incidence of mucinous adenocarcinomas in the KRAS^mt^ group was higher than in the KRAS^wt^ group. Yet, no significant difference was demonstrated (*x*^2^=0.346, *p* = 0.556) between the two groups. The observed results are listed in Table [2](#Tab2){ref-type="table"}.

ROC analysis {#Sec20}
------------

The ROC curve of the ADC values is shown in Fig. [5](#Fig5){ref-type="fig"}. The AUC of ADC values was 0.682 (95%CI: 0.564\~0.801); at a cutoff value of 1.145 × 10^− 3^ mm^2^/s, the sensitivity and specificity were 66.67, 62.12%, respectively. The ROC curve of the quantitative texture values is shown in Fig. [6](#Fig6){ref-type="fig"}. According to ROC curve, textural features: *Mean*, *Variance*, *Skewness*, *Entropy*, GLUN and RLUN values showed diagnostic significance with the AUC values of 0.754, 0.759, 0.703, 0.800, 0.802 and 0.813, respectively. The optimal cutoff values for the above features and their relevant sensitivity, and specificity are listed in Table [3](#Tab3){ref-type="table"}. Fig. 5Receiver operating characteristic (ROC) curves (solid line) and 95% confidence bounds (dotted lines) for ADC values in differentiating KRAS mutation status in rectal cancer Fig. 6Receiver operating characteristic (ROC) curves corresponding to T2W images derived quantitative texture features for differentiating KRAS mutation status in rectal cancer Table 3Receiver operator characteristics of textural parameters for predicting KRAS statusFeatureAUCSE(AUC)95%CI(AUC)CriterionSe(%)Sp(%)Mean0.7540.0400.674\~0.833\>72.07258.33%83.67%Variance0.7590.0380.684\~0.834\>281.70083.33%60.20%Skewness0.7030.0430.618\~0.787\>0.55480.00%69.39%Entropy0.8000.0350.731\~0.870\>1.89376.67%78.57%RLNU0.8020.0360.731\~0.872\>186.35078.33%76.53%GLNU0.8130.0340.746\~0.880\>7.84678.33%74.49%*Abbreviation*: *AUC* area under the curve, *SE* standard error, *Se* sensitivity, *Sp* specificity, *RLNU* run-length nonuniformity, *GLNU* gray-level nonuniformity

Interobserver agreement {#Sec21}
-----------------------

Relatively good to excellent interobserver agreement was obtained for continuous variables ADC values, tumor length, MEMD, textural features with ICC values ranging from 0.719 to 0.9487, 0.9838 to 0.9963, 0.9643 to 0.9918, and 0.6379 to 0.8159, respectively. The interobserver agreement for categorical variables measured by the Kappa value ranged from 0.729 to 1.0. EMVI had a substantial agreement (Kappa value, 0.729), while the remaining MRI features showed almost perfect agreement (Kappa value \> 0.8) (Table [4](#Tab4){ref-type="table"}). Table 4Inter-observer agreement for variablesInter-observer agreement for variablesVariable TypeVariableKappa value/ICC95%CICategoricalTumor shape0.9190.863-0.974circumferential0.9790.965-1.0T stage0.9350.883-0.986N stage0.9400.898-0.981Tumor type0.8040.663-0.945EMVI0.7290.599-0.857CRM0.8120.694-0.930ContinuousADC0.85420.7190-0.9487Tumor length0.98850.9838-0.9963MEMD0.98430.9643-0.9918Mean0.74480.6663-0.8069Variance0.75710.6818-0.8159Skewness0.74020.6607-0.8032Entropy0.74520.6670-0.8072GLNU0.72390.6379-0.7916RLNU0.75390.6776-0.8141Inter-observer agreement of categorical variables was evaluated by Kappa or weighted Kappa value, while inter-observer agreement of continuous ones was evaluated by ICC

Discussion {#Sec22}
==========

In the present study, we found that 1) the textural analysis based on T2 weighted images had robust value in differentiating KRAS status in rectal cancer; 2) rectal cancers with KRAS mutation showed lower ADC value and manifested as ulcerofungating/ ulceroinfiltrative mass or had bulky shape, behaving more aggressive to surrounding tissue with larger MEMD and higher T stage. To our knowledge, this study is the first that explored the potential of textural analysis for predicting KRAS status in rectal cancer based on MR images.

Although textural features are inconsistent for variable software vendors, the focus key in texture analysis has been on assessing heterogeneity in tumor images \[[@CR37]\]. Each texture feature measures a particular property of the arrangement of pixels within ROIs. Theoretically, a number of these features are correlated with intra-tumor heterogeneity attributed to various factors including necrosis, hypoxia, angiogenesis, hemorrhage, even genetic variations \[[@CR37]--[@CR41]\] For example, *Variance* is negatively associated with angiogenesis in CRCs without KRAS mutant, while positive association has been demonstrated between *Skewness* and angiogenesis in CRCs with KRAS mutant \[[@CR41]\]. *Entropy* derived from GLCM measures the disorder of an image \[[@CR35]\]. If the image is heterogeneous, many of the elements in the co-occurrence matrix will have very small values, thus implying a very large entropy \[[@CR42]\]. In the present study, rectal cancer with KRAS mutation had higher *Entropy* values compared to the KRAS^wt^ group (*p* \< 0.0001). In other words, rectal cancer with KRAS mutation had higher intrinsic heterogeneity than KRAS wild-type cancers did; this intrinsic heterogeneity in KARS mutation should be addressed more in detail by further research.

Encouraging results on texture analysis for differentiating benign and malignant lymph nodes, identifying T stage and predicting outcome after chemoradiotherapy in rectal cancer have been reported by previous studies using different imaging modalities including CT, MR, and ultrasound \[[@CR22]--[@CR24], [@CR43], [@CR44]\]. In this study, we performed the texture analysis of rectal cancer using T2 weighted images from MR, which is the gold-standard imaging technique for preoperative staging and is also the standard routine for patients with rectal cancer at our hospital. Furthermore, MRI could reduce the impact of image noise on biological heterogeneity with higher contrast resolution and contrast-to-noise ratio compared with CT \[[@CR24]\].

As mentioned above, the lower ADC value observed in rectal cancers with KRAS mutation may suggest an unfavorable tumor profile. Recent studies have revealed that low ADC values are associated with poorly differentiated tumors and high tumor stages in rectal cancers \[[@CR45], [@CR46]\] It is well known that ADC value is inversely correlated with the cellularity and positively correlated with necrosis and cystic changes in tissues. Hence, lower ADC value might reflect less necrosis, higher cellular density, and higher vascularization, suggesting the aggressiveness of the tumor profile \[[@CR47]\]. Furthermore, it has been reported that lung metastasis is more likely to develop in CRCs with KRAS mutation than in KRAS wild-type \[[@CR48]\]. These findings are indirectly consistent with our results.

In the present study, higher incidences of bulky CRCs were observed in the KRAS^mt^ group compared to the KRAS^wt^ group. Kim et al \[[@CR27]\] have shown a higher incidence of bulky CRCs in the poorly differentiated CRCs than in the well- or moderately differentiated CRCs, and poor differentiation is associated with high risk of postoperative relapse in stage II CRCs \[[@CR49]\]. Thus, it is proposed that bulky CRCs are more likely to have a poor prognosis. Actually, according to classification criteria \[[@CR27]\], bulky tumors had exophytic growth tendency with MEMD\> 10 mm in our study. Cho and colleagues \[[@CR49]\] have reported that significantly higher 3-year recurrence rate after surgical treatment is observed in rectal cancers with MEMD\> 10 mm than in tumors with MEMD ≤10 mm, which supported our hypothesis. Consequently, it is easy to understand the relatively higher incidence of bulky CRCs in the KRAS^mt^ group.

In daily practice, the biopsy is still the routine way to get tumour mutant status before treatment. Considering the spatial and temporal intra-tumour molecular heterogeneity, the results for biopsy samples are yet to be consistent \[[@CR11]--[@CR13], [@CR50]\]. Recently, a large prospective study \[[@CR50]\] showed that the concordance ratio between paired biopsy and resection specimens was 82% for KRAS status. In the current study, although the best sensitivity (*Variance*) and specificity (*Mean*) of the texture features were both over 83% in the study, the sensitivity and specificity of GLNU, which harboured the best diagnostic significance (AUC = 0.813), were both lower than 80%. These findings suggest that the textural analysis can potentially provide promising MRI biomarkers for KRAS status, however, the sensitivity of it still needs to be improved in further studies.

There are some limitations in the current study. First, texture features were selected using POE + ACC algorithms in combination with ANN classifiers, and merely six features were extracted for further analysis in this study. Considering that a large number of features could be generated by MaZda software and that limited subjects were included in the study selective bias may exist and further studies are required. Second, due to the complexity of the technique and a high number of parameters, high variability in data acquisition could be introduced in the MRI scan, and in theory could affect the reproducibility of the final results \[[@CR24]\]. However, the differences in texture features extracted from MR images from different scanners seem to have only a weak impact on the results of tissue discrimination \[[@CR34]\]. Third, with regard to the genomic results, our data were restricted to the KRAS mutations located in codons 12 and 13. Nevertheless, since condons 12 and 13 KRAS mutations represent the majority of RAS mutations in CRC, our results provide a reasonable representation for tumors with RAS mutation in some degree. Fourth, considering the potential discrepancy between pre-treatment biopsy and final pathology \[[@CR11]--[@CR13]\], only the outcome from final surgical specimen were enrolled in the study. Fifth, this was a single-center study with a limited sample size, which may be the reason why only moderate predictive value of MRI features for identifying KRAS status has been observed. Further work with a larger sample size may lead to more statistically significant results.

Conclusion {#Sec23}
==========

Overall, our preliminary results demonstrate that MRI features, including quantitative texture analysis derived from T2 weighted images, have the potential to differentiate the KRAS status in rectal cancers. The additional texture features may provide reference information for characterizing KRAS status with the expected impact on management of individualized diagnosis and treatment of rectal cancer.
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:   Region of interest

SD

:   Standard deviation

TE

:   Echo time

TNM

:   Tumor Node Metastasis

TR

:   Repetition time

TSE

:   Turbo spin echo

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors wish to thank Dr. Queenie Chan for her technical support in editing the manuscript.

YX, QX and HS designed the study, and drafted the manuscript. YM, JD, HZ, TL, LL, KS, SX, and WW participated in study design. YX, QX and HS carried out data collection, data analysis, and manuscript revision. All authors reviewed the data and approved the final version of the manuscript.

This work has received funding from the Beijing Municipal Science & Technology Commission (No. Z181100001718099), National Natural Science Foundation of China (81501469) and National health and family planning commission public service (201402019). The funding body had no involvement in the design of the study, collection, analysis, and interpretation of data and in writing the manuscript.

This study was approved by our institutional ethics committee. For this type of retrospective study, formal consent was not required. The study was performed in accordance with the relevant guidelines and regulations.

Not applicable.

The authors declare that they have no competing interests.
